{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:09:46Z","timestamp":1788404986123,"version":"build-2803163510"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This multicentre, observational, retrospective chart review study assessed ceftaroline fosamil treatment patterns and outcomes in adults hospitalized with community-acquired pneumonia (CAP) in usual care settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Anonymized patient data were extracted from hospital records of adults with CAP who received \u22654 consecutive IV ceftaroline fosamil doses at sites in Brazil, Colombia, France, Greece, Italy, Russia and Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The dataset included 185 patients (58.9% male; mean age 62.2\u2005years), of whom 128 (69.2%) had severe CAP defined by CURB-65, PSI\/PORT score or physician judgement. Streptococcus pneumoniae (n\u200a=\u200a44; 23.8%) and Staphylococcus aureus [MSSA (n\u200a=\u200a15) and MRSA (n\u200a=\u200a14)] were the most frequently identified pathogens. Clinical response occurred in 151 (81.6%) patients overall, and in 104 (81.3%) severe CAP patients. Response within \u22644 and &amp;gt;4\u2005days occurred in 79 (42.7%) and 62 (33.5%) patients (unknown, n\u200a=\u200a10), respectively. Twenty (10.8%) patients required readmission within 30\u2005days. Thirty-day all-cause mortality rates were 9.7% (n\u200a=\u200a18) overall and 10.2% (n\u200a=\u200a13) in severe CAP. In sensitivity analysis using ICU admission as a more objective marker of severe CAP (n\u200a=\u200a75), clinical response and 30\u2005day mortality occurred in 57 (76.0%) and 10 (13.3%) patients, respectively. Overall, clinical response to ceftaroline fosamil was associated with &amp;gt;60% shorter length of ICU stay (3.6 versus 9.2\u2005days), and &amp;gt;30% lower hospital costs ($8449 versus $12\u200a559) versus non-responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ceftaroline fosamil was effective in treating adults with CAP, including severe CAP, in Europe and Latin America. Clinical response to ceftaroline fosamil was associated with reductions in healthcare resource use compared with non-responders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlae078","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T08:12:13Z","timestamp":1715242333000},"source":"Crossref","is-referenced-by-count":5,"title":["Ceftaroline fosamil treatment patterns and outcomes in adults with community-acquired pneumonia: a real-world multinational, retrospective study"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-0811","authenticated-orcid":false,"given":"Alex","family":"Soriano","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital Cl\u00ednic de Barcelona, CIBERINF, CIBER in Infectious Diseases , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Clinica Malattie Infettive, Ospedale Policlinico IRCCS San Martino and University of Genoa , Genoa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Gogos","sequence":"additional","affiliation":[{"name":"Divison of Infectious Diseases, Department of Internal Medicine, University of Patras , Patras , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Ferry","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Croix-Rousse Hospital, Hospices Civils de Lyon , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"de Pablo","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS, University of Alcal\u00e1 , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1910-5836","authenticated-orcid":false,"given":"Wajeeha","family":"Ansari","sequence":"additional","affiliation":[{"name":"Pfizer Biopharmaceuticals Group, Pfizer , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kantecki","sequence":"additional","affiliation":[{"name":"Global Medical Affaris, Pfizer , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Schweikert","sequence":"additional","affiliation":[{"name":"Health Economics and Epidemiology, ICON plc , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Luna","sequence":"additional","affiliation":[{"name":"Health Economics and Epidemiology, ICON plc , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[{"name":"Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Milan , Italy"},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"2024062806355446800_dlae078-B1","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.vaccine.2015.05.001","article-title":"Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: a nationwide retrospective claims database analysis","volume":"33","author":"Rozenbaum","year":"2015","journal-title":"Vaccine"},{"issue":"Suppl 5","key":"2024062806355446800_dlae078-B2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1469-0691.2012.03937.x","article-title":"Understanding the burden of pneumococcal disease in adults","volume":"18","author":"Blasi","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2024062806355446800_dlae078-B3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"},{"key":"2024062806355446800_dlae078-B4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-3-319-78538-7_2","volume-title":"Antimicrobial Resistance in the 21st Century","author":"Cill\u00f3niz","year":"2018"},{"key":"2024062806355446800_dlae078-B5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1469-0691.2004.00872.x","article-title":"Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program","volume":"10","author":"Castanheira","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"2024062806355446800_dlae078-B6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S1579-2129(06)60322-4","article-title":"Update to the Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia","volume":"40","author":"Grupo de trabajo de la Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT)","year":"2004","journal-title":"Arch Bronconeumol"},{"key":"2024062806355446800_dlae078-B7","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1183\/09031936.00105211","article-title":"New guidelines for the management of adult lower respiratory tract infections","volume":"38","author":"Woodhead","year":"2011","journal-title":"Eur Respir J"},{"key":"2024062806355446800_dlae078-B8","author":"Allergan"},{"key":"2024062806355446800_dlae078-B9","author":"Pfizer"},{"issue":"Suppl 3","key":"2024062806355446800_dlae078-B10","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"2024062806355446800_dlae078-B11","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2024062806355446800_dlae078-B12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1179\/1973947814Y.0000000184","article-title":"Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience","volume":"26","author":"Ramani","year":"2014","journal-title":"J Chemother"},{"key":"2024062806355446800_dlae078-B13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(14)71018-7","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial","volume":"15","author":"Zhong","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 4","key":"2024062806355446800_dlae078-B14","first-page":"iv41","article-title":"CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 4","key":"2024062806355446800_dlae078-B15","first-page":"iv53","article-title":"CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2024062806355446800_dlae078-B16","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1093\/jac\/dkw333","article-title":"A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600\u2005mg every 8\u2005h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities","volume":"71","author":"Dryden","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2024062806355446800_dlae078-B17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cpdd.907","article-title":"Pharmacokinetic and pharmacodynamic target attainment in adult and pediatric patients following administration of ceftaroline fosamil as a 5-minute infusion","volume":"10","author":"Riccobene","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2024062806355446800_dlae078-B18","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/jac\/dkv415","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials","volume":"71","author":"Taboada","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2024062806355446800_dlae078-B19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40121-019-0243-4","article-title":"A retrospective analysis of probability of target attainment in community-acquired pneumonia: ceftaroline fosamil versus comparators","volume":"8","author":"Cristinacce","year":"2019","journal-title":"Infect Dis Ther"},{"key":"2024062806355446800_dlae078-B20","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 2","key":"2024062806355446800_dlae078-B21","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024062806355446800_dlae078-B22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00134-023-07033-8","article-title":"ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia","volume":"49","author":"Martin-Loeches","year":"2023","journal-title":"Intensive Care Med"},{"issue":"Suppl 3","key":"2024062806355446800_dlae078-B23","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1136\/thx.2009.121434","article-title":"BTS guidelines for the management of community acquired pneumonia in adults: update 2009","volume":"64","author":"Lim","year":"2009","journal-title":"Thorax"},{"key":"2024062806355446800_dlae078-B24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3111\/13696998.2013.794805","article-title":"Initial treatment failure in non-ICU community-acquired pneumonia: risk factors and association with length of stay, total hospital charges, and mortality","volume":"16","author":"Oster","year":"2013","journal-title":"J Med Econ"},{"key":"2024062806355446800_dlae078-B25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1086\/648678","article-title":"Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods","volume":"50","author":"Johansson","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024062806355446800_dlae078-B26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/cid\/ciw300","article-title":"Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes","volume":"63","author":"Self","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024062806355446800_dlae078-B27","first-page":"475","volume-title":"Community-Acquired Pneumonia","author":"Ewig","year":"2001"},{"key":"2024062806355446800_dlae078-B28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1055\/s-2005-925521","article-title":"Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study","volume":"26","author":"Ram\u00edrez","year":"2005","journal-title":"Semin Respir Crit Care Med"},{"issue":"Suppl 6","key":"2024062806355446800_dlae078-B29","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","article-title":"Guidelines for the management of adult lower respiratory tract infections\u2013full version","volume":"17","author":"Woodhead","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2024062806355446800_dlae078-B30","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/cid\/cis022","article-title":"Prevalence of methicillin-resistant Staphylococcus aureus as an etiology of community-acquired pneumonia","volume":"54","author":"Moran","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024062806355446800_dlae078-B31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/bjaed\/mkv052","article-title":"Severe community-acquired pneumonia","volume":"16","author":"Morgan","year":"2016","journal-title":"BJA Educ"},{"key":"2024062806355446800_dlae078-B32","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","article-title":"Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia","volume":"51","author":"File","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024062806355446800_dlae078-B33","doi-asserted-by":"crossref","first-page":"230117","DOI":"10.1183\/16000617.0117-2023","article-title":"Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia","volume":"32","author":"Torres","year":"2023","journal-title":"Eur Respir Rev"},{"key":"2024062806355446800_dlae078-B34","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024062806355446800_dlae078-B35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chest.2019.10.006","article-title":"Rate and predictors of bacteremia in afebrile community-acquired pneumonia","volume":"157","author":"Forstner","year":"2020","journal-title":"Chest"},{"key":"2024062806355446800_dlae078-B36","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1017\/S0950268810002402","article-title":"Outcomes of hospitalized patients with bacteraemic and non-bacteraemic community-acquired pneumonia caused by Streptococcus pneumoniae","volume":"139","author":"Lin","year":"2011","journal-title":"Epidemiol Infect"},{"key":"2024062806355446800_dlae078-B37","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1183\/09031936.00152514","article-title":"Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis","volume":"45","author":"Torres","year":"2015","journal-title":"Eur Respir J"},{"key":"2024062806355446800_dlae078-B38","doi-asserted-by":"crossref","DOI":"10.1177\/1179554918825449","article-title":"Tumor treating fields for glioblastoma treatment: patient satisfaction and compliance with the second-generation Optune\u00ae system","volume":"13","author":"Kinzel","year":"2019","journal-title":"Clin Med Insights Oncol"},{"key":"2024062806355446800_dlae078-B39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/IPC.0000000000000191","article-title":"Ceftaroline fosamil for the treatment of Staphylococcus aureus bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia","volume":"23","author":"Vazquez","year":"2015","journal-title":"Infect Dis Clin Pract (Baltim Md)"},{"key":"2024062806355446800_dlae078-B40","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/20009666.2017.1374107","article-title":"Experience with ceftaroline for treatment of methicillin-resistant Staphylococcus aureus pneumonia in a community hospital","volume":"7","author":"Karki","year":"2017","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"2024062806355446800_dlae078-B41","doi-asserted-by":"crossref","first-page":"e020243","DOI":"10.1136\/bmjopen-2017-020243","article-title":"Factors associated with 30-day readmission after hospitalisation for community-acquired pneumonia in older patients: a cross-sectional study in seven Spanish regions","volume":"8","author":"Toledo","year":"2018","journal-title":"BMJ Open"},{"key":"2024062806355446800_dlae078-B42","article-title":"Ceftaroline fosamil (CPT-F) in bacteraemia associated with community-acquired pneumonia (CAP) or acute bacterial skin and skin structure infections (ABSSSI)","author":"Golan"},{"key":"2024062806355446800_dlae078-B43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1179\/1973947815Y.0000000010","article-title":"Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP)","volume":"28","author":"Guervil","year":"2016","journal-title":"J Chemother"},{"key":"2024062806355446800_dlae078-B44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40121-014-0036-8","article-title":"Ceftaroline fosamil for the treatment of community-acquired pneumonia: from FOCUS to CAPTURE","volume":"3","author":"Carreno","year":"2014","journal-title":"Infect Dis Ther"},{"key":"2024062806355446800_dlae078-B45","doi-asserted-by":"crossref","first-page":"259A","DOI":"10.1378\/chest.1704989","article-title":"Current use of ceftaroline for community-acquired bacterial pneumonia (CABP) in US hospitals: length of stay and total cost from the CAPTURE study","volume":"144","author":"Huang","year":"2013","journal-title":"Chest"},{"key":"2024062806355446800_dlae078-B46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13696998.2019.1688819","article-title":"Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain","volume":"23","author":"Torres","year":"2020","journal-title":"J Med Econ"},{"key":"2024062806355446800_dlae078-B47","first-page":"PA238","article-title":"The economic impact of adding ceftaroline fosamil to hospital formulary for community acquired bacterial pneumonia: a hospital budget impact analysis in the United States","volume":"15","author":"Huang","year":"2012","journal-title":"Value Health"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/3\/dlae078\/58245620\/dlae078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/3\/dlae078\/58245620\/dlae078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T02:36:28Z","timestamp":1719542188000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlae078\/7682518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlae078","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,5,6]]},"article-number":"dlae078"}}